Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Liabilities and Shareholders Equity (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Liabilities and Shareholders Equity for 13 consecutive years, with $415.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 16.67% to $415.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.5 billion, a 2.41% increase, with the full-year FY2024 number at $354.2 million, changed N/A from a year prior.
  • Liabilities and Shareholders Equity was $415.5 million for Q3 2025 at Theravance Biopharma, down from $426.0 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $763.5 million in Q3 2022 to a low of $343.6 million in Q1 2025.
  • A 5-year average of $430.7 million and a median of $403.1 million in 2021 define the central range for Liabilities and Shareholders Equity.
  • Peak YoY movement for Liabilities and Shareholders Equity: skyrocketed 89.4% in 2022, then crashed 45.83% in 2023.
  • Theravance Biopharma's Liabilities and Shareholders Equity stood at $403.1 million in 2021, then soared by 50.68% to $607.4 million in 2022, then plummeted by 31.91% to $413.6 million in 2023, then dropped by 14.37% to $354.2 million in 2024, then rose by 17.31% to $415.5 million in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Liabilities and Shareholders Equity are $415.5 million (Q3 2025), $426.0 million (Q2 2025), and $343.6 million (Q1 2025).